Tags

Type your tag names separated by a space and hit enter

The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
Perspect Psychiatr Care. 2018 Oct; 54(4):507-513.PP

Abstract

PURPOSE

We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider.

DESIGN AND METHODS

Case series; inefficacy, intolerability, or other unsatisfactory outcome to previous trial with aripiprazole or bupropion.

FINDINGS

The majority of individuals in our sample exhibited tolerability of brexpiprazole. In addition, reduction in mean PHQ-9 scores was observed with brexpiprazole treatment.

IMPLICATIONS

The results of our preliminary analysis suggest that a subpopulation of adults who have insufficient outcomes on aripiprazole or bupropion due to intolerability, inefficacy or other unsatisfactory outcome may benefit by switching to brexpiprazole treatment. Larger randomized controlled trials are needed, as well as sophisticated network analysis to further understand efficacy and tolerability differences between atypical antipsychotics.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Aladeen T
Dent Neurologic Institute, Amherst, NY, USA. University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.
Westphal E
Dent Neurologic Institute, Amherst, NY, USA.
Lee Y
Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Rong C
Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Rainka M
Dent Neurologic Institute, Amherst, NY, USA.
Capote H
Dent Neurologic Institute, Amherst, NY, USA.
McIntyre RS
Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.

MeSH

AdultAntipsychotic AgentsAripiprazoleBupropionDepressive Disorder, MajorFemaleHumansMaleMiddle AgedNew YorkPsychiatric Status Rating ScalesQuinolonesRetrospective StudiesThiophenesTreatment OutcomeYoung Adult

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29427512

Citation

Aladeen, Traci, et al. "The Use of Brexpiprazole Amongst Individuals With Insufficient Outcomes With Aripiprazole or Bupropion: a Case Series." Perspectives in Psychiatric Care, vol. 54, no. 4, 2018, pp. 507-513.
Aladeen T, Westphal E, Lee Y, et al. The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. Perspect Psychiatr Care. 2018;54(4):507-513.
Aladeen, T., Westphal, E., Lee, Y., Rong, C., Rainka, M., Capote, H., & McIntyre, R. S. (2018). The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. Perspectives in Psychiatric Care, 54(4), 507-513. https://doi.org/10.1111/ppc.12258
Aladeen T, et al. The Use of Brexpiprazole Amongst Individuals With Insufficient Outcomes With Aripiprazole or Bupropion: a Case Series. Perspect Psychiatr Care. 2018;54(4):507-513. PubMed PMID: 29427512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. AU - Aladeen,Traci, AU - Westphal,Erica, AU - Lee,Yena, AU - Rong,Carola, AU - Rainka,Michelle, AU - Capote,Horacio, AU - McIntyre,Roger S, Y1 - 2018/02/10/ PY - 2017/04/21/received PY - 2017/12/22/revised PY - 2017/12/26/accepted PY - 2018/2/11/pubmed PY - 2018/12/12/medline PY - 2018/2/11/entrez KW - aripiprazole KW - bipolar disorder KW - brexpiprazole KW - major depressive disorder KW - safety KW - tolerability SP - 507 EP - 513 JF - Perspectives in psychiatric care JO - Perspect Psychiatr Care VL - 54 IS - 4 N2 - PURPOSE: We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider. DESIGN AND METHODS: Case series; inefficacy, intolerability, or other unsatisfactory outcome to previous trial with aripiprazole or bupropion. FINDINGS: The majority of individuals in our sample exhibited tolerability of brexpiprazole. In addition, reduction in mean PHQ-9 scores was observed with brexpiprazole treatment. IMPLICATIONS: The results of our preliminary analysis suggest that a subpopulation of adults who have insufficient outcomes on aripiprazole or bupropion due to intolerability, inefficacy or other unsatisfactory outcome may benefit by switching to brexpiprazole treatment. Larger randomized controlled trials are needed, as well as sophisticated network analysis to further understand efficacy and tolerability differences between atypical antipsychotics. SN - 1744-6163 UR - https://www.unboundmedicine.com/medline/citation/29427512/The_use_of_brexpiprazole_amongst_individuals_with_insufficient_outcomes_with_aripiprazole_or_bupropion:_A_case_series_ DB - PRIME DP - Unbound Medicine ER -